Researchers at the European Association for the Study of Diabetes in Milan reported encouraging results for a new class of injectable weight-loss drugs called amylins, which appear to cause fewer gastrointestinal side effects than existing GLP-1 medications. Novo Nordisk's Cagri…
New Amylin-Based Weight-Loss Drugs Show Fewer Side Effects in Late-Stage Trials
Researchers at the European Association for the Study of Diabetes in Milan reported encouraging results for a new class of injectable weight-loss drugs called amylins, which appear to cause fewer gastrointestinal side effects than existing GLP-1 medications. Novo Nordisk's CagriSema helped patients lose 22.4% of body weight, while Eli Lilly's combination drug achieved 23% weight loss.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.
Same event, other desks
Story file →
en
How Overthinkers Can Train Themselves to Take Action
01.10 09:01
uk
Goldman Sachs підвищив рейтинг Iberdrola через зростання прибутку та інвестиції в електромережі
01.10 09:01
en
Justice Department Audit Warns Cartel Surveillance Threatens Federal Agents and Families
01.10 10:01
en
Ken Griffin's $3 Billion Gift to Carnegie Mellon Reshapes Florida's Innovation Economy
01.10 10:01
pl
5 stylizacji z denimem na jesień, które pokochają fanki mody
01.10 10:01